Home Casteddu.com FAQ My Amedeo About Flying Publisher   

The Medical Article of the Year 2008:
Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-78.
Free full-text


  Prostate Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 94 articles:
HTML format



Single Articles


    July 2008
  1. BERNSTEIN WB , Kemp JD, Kim GS, Johnson VV, et al
    Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer.
    J Clin Oncol. 2008;26:3281-4.
    PubMed     Related articles   


    June 2008
  2. D'AMICO AV , Chen MH, Renshaw AA, Loffredo B, et al
    Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.
    J Clin Oncol. 2008;26:2979-83.
    PubMed     Related articles    Abstract available


  3. SANFILIPPO NJ , Taneja SS, Chachoua A, Lepor H, et al
    Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer.
    J Clin Oncol. 2008;26:2973-8.
    PubMed     Related articles    Abstract available


  4. RATHKOPF D , Carducci MA, Morris MJ, Slovin SF, et al
    Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
    J Clin Oncol. 2008;26:2959-65.
    PubMed     Related articles    Abstract available


  5. SMITH MR
    Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past?
    J Clin Oncol. 2008;26:2932-3.
    PubMed     Related articles   


  6. MAITLAND NJ , Collins AT
    Prostate cancer stem cells: a new target for therapy.
    J Clin Oncol. 2008;26:2862-70.
    PubMed     Related articles    Abstract available


  7. GLINSKY GV
    "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
    J Clin Oncol. 2008;26:2846-53.
    PubMed     Related articles    Abstract available


    May 2008
  8. HALABI S , Vogelzang NJ, Kornblith AB, Ou SS, et al
    Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
    J Clin Oncol. 2008;26:2544-9.
    PubMed     Related articles    Abstract available


  9. LOGOTHETIS CJ , Millikan R
    Chemotherapy for advanced prostate cancer: 25 years later.
    J Clin Oncol. 2008;26:2423-4.
    PubMed     Related articles   


  10. NABHAN C
    Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer?
    J Clin Oncol. 2008;26:2413-4.
    PubMed     Related articles   


  11. HU JC , Wang Q, Pashos CL, Lipsitz SR, et al
    Utilization and outcomes of minimally invasive radical prostatectomy.
    J Clin Oncol. 2008;26:2278-84.
    PubMed     Related articles    Abstract available


  12. BLUTE ML
    Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise?
    J Clin Oncol. 2008;26:2248-9.
    PubMed     Related articles   


  13. BLANCHARD CM , Courneya KS, Stein K
    Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II.
    J Clin Oncol. 2008;26:2198-204.
    PubMed     Related articles    Abstract available


    April 2008
  14. NGUYEN PL , D'Amico AV
    Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials.
    J Clin Oncol. 2008;26:2055-6.
    PubMed     Related articles   


  15. HORWITZ EM , Bae K, Hanks GE, Porter A, et al
    Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer.
    J Clin Oncol. 2008;.
    PubMed     Related articles    Abstract available


  16. BERRUTI A , Tucci M, Mosca A, Ardine M, et al
    Could the efficacy of docetaxel in prostate cancer patients be potentiated by concomitant high-dose calcitriol administration?
    J Clin Oncol. 2008;26:1900-1.
    PubMed     Related articles   


  17. SMITH MR , Malkowicz SB, Chu F, Forrest J, et al
    Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
    J Clin Oncol. 2008;26:1824-9.
    PubMed     Related articles    Abstract available


  18. HEMMINKI K , Ji J, Forsti A, Sundquist J, et al
    Concordance of survival in family members with prostate cancer.
    J Clin Oncol. 2008;26:1705-9.
    PubMed     Related articles    Abstract available


  19. PARKER C , Sydes MR
    Resolving the optimal timing of radiotherapy after radical prostatectomy: the need for further research.
    J Clin Oncol. 2008;26:e3.
    PubMed     Related articles   


    March 2008
  20. GALSKY MD , Eisenberger M, Moore-Cooper S, Kelly WK, et al
    Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2008;.
    PubMed     Related articles    Abstract available


  21. FLAIG TW , Tangen CM, Hussain MH, Stadler WM, et al
    Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
    J Clin Oncol. 2008;26:1532-6.
    PubMed     Related articles    Abstract available


  22. SHARIAT SF , Walz J, Roehrborn CG, Zlotta AR, et al
    External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
    J Clin Oncol. 2008;26:1526-31.
    PubMed     Related articles    Abstract available


  23. VIKRAM B
    Does postoperative radiation therapy benefit patients with prostate cancer?
    J Clin Oncol. 2008;26:1392.
    PubMed     Related articles   


  24. SCHER HI , Halabi S, Tannock I, Morris M, et al
    Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
    J Clin Oncol. 2008;26:1148-59.
    PubMed     Related articles    Abstract available


  25. GEMMEL FF , De Geeter FW
    Magnetic resonance imaging versus bone scan in high-risk prostatic carcinoma: some methodological considerations.
    J Clin Oncol. 2008;26:1189-90.
    PubMed     Related articles   


  26. ANKER CJ , Dechet C, Isaac JC, Akerley W, et al
    Small-cell carcinoma of the prostate.
    J Clin Oncol. 2008;26:1168-71.
    PubMed     Related articles   


    February 2008
  27. ROSS RW , Oh WK, Xie W, Pomerantz M, et al
    Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    J Clin Oncol. 2008;26:842-7.
    PubMed     Related articles    Abstract available


  28. ULMERT D , Serio AM, O'Brien MF, Becker C, et al
    Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened popul
    J Clin Oncol. 2008;26:835-41.
    PubMed     Related articles    Abstract available


  29. D'AMICO AV
    Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    J Clin Oncol. 2008;26:823-4.
    PubMed     Related articles   


  30. MOHAN R
    Family physicians could help in predicting life expectancy without prostate cancer.
    J Clin Oncol. 2008;26:690-1.
    PubMed     Related articles   


  31. FLETCHER BS , Paul SM, Dodd MJ, Schumacher K, et al
    Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer.
    J Clin Oncol. 2008;26:599-605.
    PubMed     Related articles    Abstract available


  32. FROEHNER M
    Life expectancy estimation by nomogram.
    J Clin Oncol. 2008;26:690.
    PubMed     Related articles   


  33. VELICER CM , Ulrich CM
    Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review.
    J Clin Oncol. 2008;26:665-73.
    PubMed     Related articles    Abstract available


    January 2008
  34. BERTHOLD DR , Pond GR, Soban F, de Wit R, et al
    Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
    J Clin Oncol. 2008;26:242-5.
    PubMed     Related articles    Abstract available


  35. GOITEIN M , Cox JD
    Should randomized clinical trials be required for proton radiotherapy?
    J Clin Oncol. 2008;26:175-6.
    PubMed     Related articles   


  36. ROACH M 3RD , Bae K, Speight J, Wolkov HB, et al
    Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610.
    J Clin Oncol. 2008;.
    PubMed     Related articles    Abstract available


  37. MOINPOUR CM , Hayden KA, Unger JM, Thompson IM Jr, et al
    Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.
    J Clin Oncol. 2008;26:112-20.
    PubMed     Related articles    Abstract available


    December 2007
  38. VENKITARAMAN R , Sohaib A, Cook G
    MRI or bone scan or both for staging of prostate cancer?
    J Clin Oncol. 2007;25:5837-8.
    PubMed     Related articles   


  39. GHOBADI A , Kabbani W, Barker B, Dowell JE, et al
    Rectal GI stromal tumor mimicking a prostate mass.
    J Clin Oncol. 2007;25:5827-8.
    PubMed     Related articles   


  40. COLLETTE L , Buyse M, Burzykowski T
    Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
    J Clin Oncol. 2007;25:5673-4.
    PubMed     Related articles   


  41. VAN DER KWAST TH , Collette L, Bolla M
    Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer.
    J Clin Oncol. 2007;25:5671-2.
    PubMed     Related articles   


  42. SHAHINIAN VB , Kuo YF, Freeman JL, Orihuela E, et al
    Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.
    J Clin Oncol. 2007;25:5359-65.
    PubMed     Related articles    Abstract available


  43. SAIGAL CS
    Moving beyond guidelines to improve the quality of care for men with prostate cancer.
    J Clin Oncol. 2007;25:5348-9.
    PubMed     Related articles   


  44. POMMIER P , Chabaud S, Lagrange JL, Richaud P, et al
    Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.
    J Clin Oncol. 2007;25:5366-73.
    PubMed     Related articles    Abstract available


    November 2007
  45. ROACH M 3RD
    Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk?
    J Clin Oncol. 2007;25:5325-6.
    PubMed     Related articles   


  46. ANTONARAKIS ES , Blackford AL, Garrett-Mayer E, Eisenberger MA, et al
    Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.
    J Clin Oncol. 2007;25:4998-5008.
    PubMed     Related articles    Abstract available


    October 2007
  47. BASCH EM , Somerfield MR, Beer TM, Carducci MA, et al
    American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer.
    J Clin Oncol. 2007;.
    PubMed     Related articles    Abstract available


    September 2007
  48. VAN DER KWAST TH , Bolla M, Van Poppel H, Van Cangh P, et al
    Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.
    J Clin Oncol. 2007;25:4178-86.
    PubMed     Related articles    Abstract available


  49. ARMSTRONG AJ , Garrett-Mayer E, Ou Yang YC, Carducci MA, et al
    Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    J Clin Oncol. 2007;25:3965-70.
    PubMed     Related articles    Abstract available


    August 2007
  50. NAM RK , Toi A, Klotz LH, Trachtenberg J, et al
    Assessing individual risk for prostate cancer.
    J Clin Oncol. 2007;25:3582-8.
    PubMed     Related articles    Abstract available


  51. WALZ J , Gallina A, Saad F, Montorsi F, et al
    A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer.
    J Clin Oncol. 2007;25:3576-81.
    PubMed     Related articles    Abstract available


  52. ROSS RW , Kantoff PW
    Predicting outcomes in prostate cancer: how many more nomograms do we need?
    J Clin Oncol. 2007;25:3563-4.
    PubMed     Related articles   


  53. KONSKI A , Speier W, Hanlon A, Beck JR, et al
    Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
    J Clin Oncol. 2007;25:3603-8.
    PubMed     Related articles    Abstract available


  54. CUSSENOT O , Azzouzi AR, Nicolaiew N, Fromont G, et al
    Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
    J Clin Oncol. 2007;25:3596-602.
    PubMed     Related articles    Abstract available


  55. ZIETMAN AL
    The Titanic and the Iceberg: prostate proton therapy and health care economics.
    J Clin Oncol. 2007;25:3565-6.
    PubMed     Related articles   


  56. CAI T , Bartoletti R
    Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
    J Clin Oncol. 2007;25:3385.
    PubMed     Related articles   


  57. LECOUVET FE , Geukens D, Stainier A, Jamar F, et al
    Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.
    J Clin Oncol. 2007;25:3281-7.
    PubMed     Related articles    Abstract available


    July 2007
  58. STALMEIER PF , van Tol-Geerdink JJ, van Lin EN, Schimmel E, et al
    Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy.
    J Clin Oncol. 2007;25:3096-100.
    PubMed     Related articles    Abstract available


  59. CHAKRAVARTI A , Desilvio M, Zhang M, Grignon D, et al
    Prognostic Value of p16 in Locally Advanced Prostate Cancer: A Study Based on Radiation Therapy Oncology Group Protocol 9202.
    J Clin Oncol. 2007;25:3082-9.
    PubMed     Related articles    Abstract available


  60. THOMPSON IM , Pauler Ankerst D, Chi C, Goodman PJ, et al
    Prediction of prostate cancer for patients receiving finasteride: results from the prostate cancer prevention trial.
    J Clin Oncol. 2007;25:3076-81.
    PubMed     Related articles    Abstract available


  61. DE VERE WHITE RW
    Finasteride for chemoprevention of prostate cancer: why has it not been embraced?
    J Clin Oncol. 2007;25:2999-3000.
    PubMed     Related articles   


  62. NORTHOUSE LL , Mood DW, Montie JE, Sandler HM, et al
    Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life.
    J Clin Oncol. 2007;.
    PubMed     Related articles    Abstract available


  63. TALCOTT JA
    Prostate Cancer Quality of Life: Beyond Initial Treatment--and the Patient.
    J Clin Oncol. 2007;.
    PubMed     Related articles   


  64. DEMARK-WAHNEFRIED W , Clipp EC, Lipkus IM, Lobach D, et al
    Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors.
    J Clin Oncol. 2007;25:2709-18.
    PubMed     Related articles    Abstract available


    June 2007
  65. SMITH DP , Supramaniam R, King MT, Ward J, et al
    Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer.
    J Clin Oncol. 2007;25:2560-6.
    PubMed     Related articles    Abstract available


  66. D'AMICO AV , Denham JW, Crook J, Chen MH, et al
    Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
    J Clin Oncol. 2007;25:2420-5.
    PubMed     Related articles    Abstract available


  67. MENENDEZ JA , Lupu R
    Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
    J Clin Oncol. 2007;25:2496-8.
    PubMed     Related articles   


  68. SWANSON GP , Hussey MA, Tangen CM, Chin J, et al
    Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.
    J Clin Oncol. 2007;25:2225-9.
    PubMed     Related articles    Abstract available


    May 2007
  69. STEPHENSON AJ , Scardino PT, Kattan MW, Pisansky TM, et al
    Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
    J Clin Oncol. 2007;25:2035-41.
    PubMed     Related articles    Abstract available


  70. HORIOT JC
    Radiation therapy and the geriatric oncology patient.
    J Clin Oncol. 2007;25:1930-5.
    PubMed     Related articles    Abstract available


  71. FREEDLAND SJ , Humphreys EB, Mangold LA, Eisenberger M, et al
    Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
    J Clin Oncol. 2007;25:1765-71.
    PubMed     Related articles    Abstract available


    April 2007
  72. GOVINDARAJAN R , Ratnasinghe L, Simmons DL, Siegel ER, et al
    Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.
    J Clin Oncol. 2007;25:1476-81.
    PubMed     Related articles    Abstract available


  73. JURASKOVA I , Butow P, Lopez AL, Seccombe M, et al
    Improving informed consent in clinical trials: successful piloting of a decision aid.
    J Clin Oncol. 2007;25:1443-4.
    PubMed     Related articles   


  74. LOBLAW DA , Virgo KS, Nam R, Somerfield MR, et al
    Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2006 Update of an American Society of Clinical Oncology Practice Guideline.
    J Clin Oncol. 2007;.
    PubMed     Related articles    Abstract available


    March 2007
  75. MICHAELSON MD , Kaufman DS, Lee H, McGovern FJ, et al
    Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    J Clin Oncol. 2007;25:1038-42.
    PubMed     Related articles    Abstract available


  76. HIGANO CS
    Annual zoledronic acid: is less more?
    J Clin Oncol. 2007;25:1026.
    PubMed     Related articles   


  77. SPEIGHT JL , Roach M 3rd
    Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy.
    J Clin Oncol. 2007;25:987-95.
    PubMed     Related articles    Abstract available


  78. BRADA M , Pijls-Johannesma M, De Ruysscher D
    Proton therapy in clinical practice: current clinical evidence.
    J Clin Oncol. 2007;25:965-70.
    PubMed     Related articles   


  79. SCHULZ-ERTNER D , Tsujii H
    Particle radiation therapy using proton and heavier ion beams.
    J Clin Oncol. 2007;25:953-64.
    PubMed     Related articles    Abstract available


    February 2007
  80. AGUS DB , Sweeney CJ, Morris MJ, Mendelson DS, et al
    Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
    J Clin Oncol. 2007;25:675-81.
    PubMed     Related articles    Abstract available


  81. BEER TM , Ryan CW, Venner PM, Petrylak DP, et al
    Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    J Clin Oncol. 2007;25:669-74.
    PubMed     Related articles    Abstract available


  82. LILJA H , Ulmert D, Bjork T, Becker C, et al
    Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
    J Clin Oncol. 2007;25:431-6.
    PubMed     Related articles    Abstract available


  83. SHARIAT SF , Roehrborn CG, McConnell JD, Park S, et al
    Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    J Clin Oncol. 2007;25:349-55.
    PubMed     Related articles    Abstract available


  84. LILJA H , Vickers A, Scardino P
    Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer.
    J Clin Oncol. 2007;25:347-8.
    PubMed     Related articles   


    January 2007
  85. DE BONO JS , Bellmunt J, Attard G, Droz JP, et al
    Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
    J Clin Oncol. 2007;25:257-62.
    PubMed     Related articles    Abstract available


  86. SOLIT DB , Rosen N
    Targeting HER2 in prostate cancer: where to next?
    J Clin Oncol. 2007;25:241-3.
    PubMed     Related articles   


  87. HEYMANN JJ , Benson MC, O'Toole KM, Malyszko B, et al
    Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    J Clin Oncol. 2007;25:77-84.
    PubMed     Related articles    Abstract available


  88. D'AMICO AV
    Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer.
    J Clin Oncol. 2007;25:8-9.
    PubMed     Related articles   


    December 2006
  89. TAPLIN ME , Xie W, Bubley GJ, Ernstoff MS, et al
    Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
    J Clin Oncol. 2006;24:5408-13.
    PubMed     Related articles    Abstract available


    November 2006
  90. CHEN AB , D'Amico AV, Neville BA, Earle CC, et al
    Patient and treatment factors associated with complications after prostate brachytherapy.
    J Clin Oncol. 2006;24:5298-304.
    PubMed     Related articles    Abstract available


  91. SIEMES C , Visser LE, Coebergh JW, Splinter TA, et al
    C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
    J Clin Oncol. 2006;24:5216-22.
    PubMed     Related articles    Abstract available


  92. GULLEY JL , Parnes HL, Wright J, Dahut WL, et al
    Early treatment gets the benefit.
    J Clin Oncol. 2006;24:5172-3.
    PubMed     Related articles   


    October 2006
  93. VAN TOL-GEERDINK JJ , Stalmeier PF, van Lin EN, Schimmel EC, et al
    Do patients with localized prostate cancer treatment really want more aggressive treatment?
    J Clin Oncol. 2006;24:4581-6.
    PubMed     Related articles    Abstract available


    July 2006
  94. WEISCHER M , Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, et al
    Increased Risk of Breast Cancer Associated With CHEK2*1100delC.
    J Clin Oncol. 2006;.
    PubMed     Related articles    Abstract available


Thank you for your interest in scientific medicine.


Amedeo is a Bernd Sebastian Kamps website.

   Design: